JPRN-jRCTs032230463
Recruiting
Phase 1
Focused Research On Neurofeedback Therapy In Eradicating Depression (FRONTIER)
Oribe Naoya0 sites30 target enrollmentNovember 20, 2023
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Depression
- Sponsor
- Oribe Naoya
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Adults (at least 18 years old at the time consent is obtained)
- •2\. Major depressive episode as defined by the diagnostic criteria of the DSM 5
- •3\. One of the following
- •a. Hamilton Depression Rating Score (HDRS 17\) of 19 or higher
- •b. Montgomery Asberg Depression Rating Scale score of 20 or higher
- •c. Any other patient deemed appropriate by the PI (subprincipal investigator)
- •4\. In the 6 weeks prior to enrollment, any of the following
- •a. not taking antidepressants
- •b.Stable antidepressant medication and agrees to remain on the same medication during study
- •5\. With stable psychotherapy for at least 6 weeks prior to enrollment and agrees to continue the same psychotherapy for the duration of study
Exclusion Criteria
- •1\. High risk of suicide, such as suicidal ideation or suicide attempts
- •2\. History of hospitalization for depression or suicidal behavior
- •3\. Comorbid addictions (drugs, alcohol) or history of addictions
- •4\. Organic brain disease (e.g., moderate or severe intracranial organic lesions or neurodegenerative disease)
- •5\. History of seizures or epilepsy
- •6\. Has a serious or unstable physical disease
- •7\. Difficulty or inappropriateness/contraindication to MRI imaging
- •8\. Pregnant women or unwilling to practice contraception during the study
- •9\. Participating in another clinical trial at the same time, or have participated in a clinical trial within the past 90 days, or are scheduled to participate in another clinical trial during the study period, and the principal (sub)investigator determines that participation in another clinical trial may interfere with the results of this study
- •10\. Other cases in which the principal investigator (or subinvestigator) determines that it is difficult to conduct this study safely.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
The development of treatment using neurofeedback (NFB) for patients with mood disorderMood disorders (major depressive disorder and bipolar disorder) and healthy volunteersJPRN-jRCTs062180027Okada Go130
Recruiting
Not Applicable
The development of treatment using neurofeedback for patients with mood disorder: an exploratory study through neuroimaging approachesMood disorders (major depressive disorder and bipolar disorder) and healthy volunteersJPRN-UMIN000019483Department of Psychiatry and Neurosciences, Graduate school of Biomedical and Health Sciences, Hiroshima University210
Completed
Not Applicable
The development of treatment using the neurofeedback for patients with obsessive-compulsive disorderObsessve-compulsive disorderJPRN-UMIN000013123Graduate School of Medical Science, Kyoto Prefectural University of Medicine20
Recruiting
Phase 1
Focused Research On Neurofeedback Therapy In Eradicating Depression (FRONTIER)DepressionNCT06557525UNB Sumiyoshi Jinja Mae Clinic30
Completed
Phase 2
Therapeutic Effects of Neurofeedback in Neurological DisordersJPRN-UMIN000010723Dept. of Neurology, Osaka University Graduate School of Medicine117